Medmira (TSE:MIR) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medmira Inc. has successfully launched its FDA-approved Reveal G4 Rapid HIV 1/2 test, expanded its distribution network, and secured significant new clients in Q3 FY2024. In addition, the company has received funding for clinical trials in Canada for its Complete Syphilis test. Despite these developments, Medmira experienced a decline in revenue and gross profit compared to the previous quarter and recorded a net loss.
For further insights into TSE:MIR stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money